IN2012DN03921A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03921A
Authority: IN; India
Prior art keywords: peptide; diabetes; insulin; disorders; glp
Prior art date: 2004-02-11

Application number

Other languages

English (en)

Inventor

Odile Esther Levy

Michael R Hanley

Carolyn M Jodka

Diana Y Lewis

Christopher J Soares

Soumitra S Ghosh

Souza Lawrence J D

David G Parkes

Christine M Mack

Original Assignee

Amylin Pharmaceuticals Inc

Astrazeneca Pharmaceuticals Lp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-11

Filing date

2005-02-11

Publication date

2015-09-04

2005-02-11 Application filed by Amylin Pharmaceuticals Inc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Inc

2015-09-04 Publication of IN2012DN03921A publication Critical patent/IN2012DN03921A/en

Links

206010012601 diabetes mellitus Diseases 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
102000004379 Adrenomedullin Human genes 0.000 abstract 2
101800004616 Adrenomedullin Proteins 0.000 abstract 2
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 2
108060001064 Calcitonin Proteins 0.000 abstract 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 2
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
102400000319 Oxyntomodulin Human genes 0.000 abstract 2
101800001388 Oxyntomodulin Proteins 0.000 abstract 2
108010088847 Peptide YY Proteins 0.000 abstract 2
102100029909 Peptide YY Human genes 0.000 abstract 2
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 2
229960004015 calcitonin Drugs 0.000 abstract 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000030159 metabolic disease Diseases 0.000 abstract 2
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
101800001982 Cholecystokinin Proteins 0.000 abstract 1
102100025841 Cholecystokinin Human genes 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
108010011459 Exenatide Proteins 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
108010092277 Leptin Proteins 0.000 abstract 1
102000016267 Leptin Human genes 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940107137 cholecystokinin Drugs 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 abstract 1
229940039781 leptin Drugs 0.000 abstract 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 abstract 1
SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

IN3921DEN2012 2004-02-11 2005-02-11 IN2012DN03921A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54340704P	2004-02-11	2004-02-11
PCT/US2005/004178 WO2005077072A2 (fr)	2004-02-11	2005-02-11	Polypeptides hybrides presentant des proprietes pouvant etre choisies

Publications (1)

Publication Number	Publication Date
IN2012DN03921A true IN2012DN03921A (fr)	2015-09-04

Family

ID=34860419

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3921DEN2012 IN2012DN03921A (fr)	2004-02-11	2005-02-11

Country Status (14)

Country	Link
US (1)	US20060094652A1 (fr)
EP (4)	EP2422806A3 (fr)
JP (2)	JP2007525495A (fr)
KR (3)	KR20120034237A (fr)
CN (3)	CN102174115B (fr)
AU (1)	AU2005211755B2 (fr)
BR (1)	BRPI0507594A (fr)
CA (2)	CA2555877C (fr)
IL (1)	IL177229A0 (fr)
IN (1)	IN2012DN03921A (fr)
NZ (2)	NZ579621A (fr)
RU (1)	RU2378285C2 (fr)
WO (1)	WO2005077072A2 (fr)
ZA (1)	ZA200607190B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20090281032A1 (en) *	2001-03-01	2009-11-12	Peter Raymond Flatt	Modified CCK peptides
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE471340T1 (de) *	2004-02-11	2010-07-15	Amylin Pharmaceuticals Inc	Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US7399744B2 (en) *	2004-03-04	2008-07-15	Amylin Pharmaceuticals, Inc.	Methods for affecting body composition
WO2006049681A2 (fr) *	2004-08-30	2006-05-11	Bayer Pharmaceuticals Corporation	Agonistes recepteur y2 neuropeptidiques selectifs
CA2580991A1 (fr) *	2004-10-08	2006-04-20	Amylin Pharmaceuticals, Inc.	Analogues de polypeptide-6 de la famille de l'amyline (afp-6) et methodes pour les produire
WO2007055728A1 (fr) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Traitement de l'obesite et de troubles associes
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr)	2005-02-03	2006-08-10	Alza Corporation	Solutions de solvant/polymere utilisees comme vehicules de suspension
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (ko)	2005-02-11	2007-12-06	아밀린 파마슈티칼스, 인크.	선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2007022123A2 (fr) *	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides presentant des proprietes selectionnables
WO2007017892A2 (fr) *	2005-05-05	2007-02-15	Cadila Healthcare Limited	Nouveaux composes utilises en tant qu'agonistes de glp-i
WO2007014051A2 (fr) *	2005-07-22	2007-02-01	Amylin Pharmaceuticals, Inc.	Utilisation d'amyline et d'agonistes d'amyline comme agents cardioprotecteurs ou myoprotecteurs
EP2330125A3 (fr)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides ayant des propriétés sélectionnables
MX2008002028A (es) *	2005-08-11	2008-03-27	Amylin Pharmaceuticals Inc	Polipeptidos hibridos con propiedades de seleccion.
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
WO2007055743A2 (fr) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Procédés pour traiter l'obésité et des troubles associés
CA2638800A1 (fr) *	2006-02-22	2007-09-07	Merck & Co., Inc.	Derives d'oxyntomoduline
JP5252435B2 (ja) *	2006-03-15	2013-07-31	ノボ・ノルデイスク・エー／エス	アミリン誘導体
WO2007109354A2 (fr) *	2006-03-21	2007-09-27	Amylin Pharmaceuticals, Inc.	Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
EP1854455B1 (fr)	2006-05-10	2009-10-07	Biocompatibles UK Limited	Microcapsules sphériques contenant des peptides du type GLP-1, leur production et leur utilisation
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
WO2008005527A2 (fr) *	2006-07-06	2008-01-10	Amylin Pharmaceuticals, Inc.	Peptides semblables au glucagon et leurs utilisations
BRPI0714886B8 (pt)	2006-07-10	2021-05-25	Paion Uk Ltd	sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
EP2359808B1 (fr)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Système de libération osmotique avec ensemble de piston
WO2008021560A2 (fr) *	2006-08-17	2008-02-21	Amylin Pharmaceuticals, Inc.	Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
EP1972349A1 (fr) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation
WO2008133908A2 (fr)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Formulations en suspension de peptides insulinotropes et leurs utilisations
AP2009005091A0 (en) *	2007-07-06	2009-12-31	Theratechnologies Inc	Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (ALPHA-MSH) and atrial natriuretic protein (ANP) and uses in hypertension andacute kidney injury
CA2726861C (fr) *	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
WO2009143285A2 (fr)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendines pour diminuer le cholestérol et les triglycérides
ES2662501T3 (es)	2008-10-21	2018-04-06	Novo Nordisk A/S	Derivados de amilina
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2416797A4 (fr)	2009-04-10	2013-04-24	Amylin Pharmaceuticals Llc	Composés agonistes de l'amyline pour mammifères ayant une carence en strogènes
EP2435061A4 (fr)	2009-05-28	2013-03-27	Amylin Pharmaceuticals Inc	Composés agonistes du récepteur glp-1 pour amélioration du sommeil
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2504021A4 (fr)	2009-11-23	2013-05-15	Amylin Pharmaceuticals Llc	Conjugué de polypeptide
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
CN107129538B (zh) *	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
EP2450039A1 (fr)	2010-11-08	2012-05-09	PAION UK Ltd.	Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
SI2651398T1 (en)	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US9161953B2 (en)	2010-12-22	2015-10-20	Amylin Pharmaceuticals, Llc	GLP-1 receptor agonists for islet cell transplantation
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2714069A4 (fr)	2011-05-25	2015-06-24	Amylin Pharmaceuticals Llc	Conjugués de deux hormones longue durée
TW201326194A (zh) *	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
JP6538645B2 (ja) *	2013-03-14	2019-07-03	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン‐インクレチン複合物
KR102272671B1 (ko)	2013-05-02	2021-07-06	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (fr)	2013-11-06	2015-05-14	Zealand Pharma A/S	Composés agonistes doubles de gip et glp-1 et procédés associés
CN105722526B (zh)	2013-11-15	2020-12-08	诺和诺德股份有限公司	选择性pyy化合物及其用途
EP3068795B1 (fr)	2013-11-15	2019-03-06	Novo Nordisk A/S	Beta-homo arginine substitution au position 35 de hpyy(1-36)
EP3080152A1 (fr)	2013-12-13	2016-10-19	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
WO2015086733A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
WO2015086728A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
EP3080154B1 (fr)	2013-12-13	2018-02-07	Sanofi	Agonistes doubles du récepteur glp-1/gip
CN103665148B (zh) *	2013-12-17	2016-05-11	中国药科大学	一种可口服给药的降糖多肽及其制法和用途
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016044224A1 (fr)	2014-09-15	2016-03-24	Amgen Inc.	Protéines de liaison antigéniques bispécifiques anti-récepteur cgrp/récepteur pac1 et leurs utilisations
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
BR112017019378A2 (pt)	2015-03-18	2019-02-19	Zealand Pharma A/S	análogos de amilina
TWI799849B (zh)	2015-04-24	2023-04-21	美商安美基公司	治療或預防偏頭痛之方法
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TWI694082B (zh)	2015-06-12	2020-05-21	丹麥商諾佛儂迪克股份有限公司	選擇性ｐｙｙ化合物及其用途
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
UA127495C2 (uk)	2015-12-23	2023-09-13	Амджен Інк.	Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CA3035561A1 (fr) *	2016-09-02	2018-03-08	Christopher J. Soares	Utilisation d'antagonistes du recepteur cgrp en neuroprotection et pour le traitement de troubles neurologiques
US10071140B2 (en)	2016-09-09	2018-09-11	Zealand Pharma A/S	Amylin analogues
US11285180B2 (en)	2016-12-06	2022-03-29	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
EP3551651B1 (fr)	2016-12-09	2024-03-06	Zealand Pharma A/S	Doubles agonistes glp-1/glp-2 acylés
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
IL313587A (en)	2017-01-17	2024-08-01	Amgen Inc	Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
EA201992502A1 (ru)	2017-06-20	2020-04-22	Эмджен Инк.	Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (fr)	2017-06-21	2020-04-29	Amgen Inc.	Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
JP7840636B2 (ja)	2018-04-02	2026-04-06	アムジェンインコーポレイテッド	エレヌマブ組成物及びその使用
TWI847981B (zh) *	2018-04-25	2024-07-11	比利時商健生藥品公司	類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
US11780900B2 (en)	2018-04-25	2023-10-10	Janssen Sciences Ireland Unlimited Company	Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
WO2020019813A1 (fr) *	2018-07-25	2020-01-30	中国药科大学	Peptide d'oxyntomoduline hybride à action prolongée, son procédé de préparation et son utilisation
AR116632A1 (es)	2018-10-11	2021-05-26	Intarcia Therapeutics Inc	Polipéptidos análogos de la amilina humana y sus métodos de uso
WO2020185533A1 (fr)	2019-03-08	2020-09-17	Amgen Inc.	Polythérapie par facteur de différenciation de croissance 15
WO2020205909A2 (fr) *	2019-04-01	2020-10-08	Doyle Robert P	Multi-agoniste peptidique monomère ciblant le récepteur glp1 et les récepteurs npy
KR102288716B1 (ko) *	2019-10-30	2021-08-12	경상남도	항비만 효능을 갖는 펩타이드 및 이의 용도
CR20220206A (es)	2019-11-11	2022-06-16	Boehringer Ingelheim Int	Agonistas del receptor npy2
JP7661478B2 (ja)	2020-08-07	2025-04-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性ｎｐｙ２受容体アゴニスト
FI4021929T3 (fi) *	2020-09-24	2023-06-14	Gubra Aps	HAM15-52-analogeja, joilla on parannettu teho amyliinireseptoriin (HAMY3R)
TWI850611B (zh) *	2020-12-18	2024-08-01	丹麥商諾佛儂迪克股份有限公司	Glp-1及澱粉素受體之共促效劑
TWI815327B (zh) *	2021-03-03	2023-09-11	美商美國禮來大藥廠	長效澱粉素受體促效劑及其用途
CN113929737B (zh) *	2021-10-20	2024-07-23	中国科学院香港创新研究院再生医学与健康创新中心	一种多肽及其作为cck受体激动剂/拮抗剂的应用
WO2024123812A1 (fr)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Protéines de fusion pour le traitement de maladies cardiométaboliques
US12533394B2 (en) *	2023-11-15	2026-01-27	Glycomantra Inc.	Compositions and methods for treating metabolic disorders

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3490597A (en)	1966-07-22	1970-01-20	Purolator Products Inc	Cover plate for spin-on-filter
DE3065460D1 (en) *	1979-07-28	1983-12-08	Beecham Group Plc	Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
US4401593A (en)	1982-02-12	1983-08-30	Armour Pharmaceutical Company	Glycine - 8 calcitonin
US4397780A (en)	1982-02-12	1983-08-09	Armour Pharmaceutical Company	Leucine22 -calcitonin
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4414149A (en) *	1983-03-04	1983-11-08	Armour Pharmaceutical Company	Glycine8 -D-arginine24 calcitonin
US4497731A (en)	1983-04-04	1985-02-05	Armour Pharmaceutical Company	Glycine 8-des-tyrosine 22 calcitonin
US4495097A (en)	1983-04-04	1985-01-22	Armour Pharmaceutical Company	Des-serine2 -glycine8 calcitonin
US5188666A (en)	1983-06-30	1993-02-23	Boccardo Victor N	Paint removing compositions and methods for the manufacture and use thereof
US4597900A (en)	1983-08-22	1986-07-01	Armour Pharmaceutical Co.	Des2 -glycine8 -des22 -calcitonin
US4537716A (en)	1983-12-05	1985-08-27	Armour Pharmaceutical Co.	Des-serine2 or des-glycine2 -leucine22 calcitonin
US4604238A (en)	1984-12-10	1986-08-05	Armour Pharmaceutical Company	Analogs of calcitonin
US4606856A (en)	1985-03-18	1986-08-19	Seyler Jay K	[Des-1-amino, 8-glycine]calcitonin
US4652627A (en) *	1985-08-16	1987-03-24	Kempe Tomas G	Calcitonin analogs with C-terminal D-amino acid substituents
US4697002A (en)	1985-12-23	1987-09-29	Kempe Tomas G	Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
US4687839A (en)	1985-12-23	1987-08-18	Kempe Tomas G	Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
KR0133561B1 (ko)	1988-05-13	1998-04-21	스티븐 엠. 오드레	과립구 군체 자극인자의 정제방법
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5234906A (en)	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
HU222249B1 (hu)	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5445781A (en)	1991-08-28	1995-08-29	Centro Sviluppo Settori Impiego S.R.L.	Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
KR960701653A (ko) *	1993-03-29	1996-03-28	발라수브라마니암 엠비카이파칸	펩타이드 yy의 유사체 및 그의 용도
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5814316A (en) *	1994-08-05	1998-09-29	Wisconsin Alumni Research Foundation	Compound to mimick a naturally occurring peptide's effect
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en)	1994-11-14	1996-11-12	The Regents Of The University Of California	Treatment of pancreatic tumors with peptide YY and analogs thereof
US5532336A (en)	1995-01-31	1996-07-02	Eli Lilly And Company	Anti-obesity proteins
US5521283A (en)	1995-01-31	1996-05-28	Eli Lilly And Company	Anti-obesity proteins
US5739106A (en) *	1995-06-07	1998-04-14	Rink; Timothy J.	Appetite regulating compositions
HUP9802609A2 (hu)	1995-06-30	1999-03-29	Eli Lilly And Co.	A diabetes kezelésére szolgáló eljárás
WO1997015322A1 (fr)	1995-10-25	1997-05-01	The Regents Of The University Of California	Procede pour retablir ou stimuler les fonctions de la reproduction chez des hotes presentant un dysfonctionnement des fonctions de la reproduction
WO1997026321A2 (fr) *	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Expression recombinee de proteines a partir de lignees cellulaires secretoires
WO1997027286A1 (fr)	1996-01-23	1997-07-31	Progenitor, Inc.	Procedes d'utilisation du gene obese et de son produit genique afin de stimuler le developpement des cellules hematopoïetiques
KR20000016402A (ko)	1996-06-06	2000-03-25	피터 기딩스	렙틴(ob단백질)의 프레그먼트
US5686511A (en) *	1996-06-28	1997-11-11	The Valspar Corporation	Esterifying epoxy resin with carboxyl polymer and quenching
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998012224A1 (fr)	1996-09-20	1998-03-26	Hoechst Aktiengesellschaft	Utilisation d'antagonistes de la leptine pour le traitement de la resistance insulinique dans les diabetes non insulino-dependants
WO1998018486A1 (fr)	1996-10-25	1998-05-07	Icogen Corporation	Utilisation de la leptine pour stimuler l'hematopoiese
DE122007000044I2 (de) *	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
AU6656098A (en)	1997-02-25	1998-09-09	Eli Lilly And Company	Treatment of infertility with leptin receptor ligands
IL120733A0 (en)	1997-04-29	1997-08-14	Yeda Res & Dev	Leptin as an inhibitor of cell proliferation
US7910548B2 (en)	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
WO1998055139A1 (fr)	1997-06-06	1998-12-10	Smithkline Beecham Plc	Utilisation d'antagonistes de leptine pour traiter le diabete
ES2293688T5 (es)	1997-08-08	2011-05-04	Amylin Pharmaceuticals, Inc.	Nuevos compuestos análogos de la exendina.
ATE383867T1 (de)	1997-11-14	2008-02-15	Amylin Pharmaceuticals Inc	Neuartige exendin agonisten
MXPA00004670A (es)	1997-11-14	2003-07-14	Amylin Pharmaceuticals Inc	Compuestos agonistas de exendina novedosos.
US7396809B1 (en) *	1999-02-10	2008-07-08	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
US7745216B2 (en)	1999-02-10	2010-06-29	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
US6162260A (en)	1999-05-24	2000-12-19	Novo Nordisk Biochem North America, Inc.	Single-bath biopreparation and dyeing of textiles
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (fr)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides abaissant le taux de glucose sanguin
US6734166B1 (en)	2000-02-08	2004-05-11	North Carolina State University	Method of reducing aluminum levels in the central nervous system
US6602997B2 (en)	2000-04-27	2003-08-05	Shin-Etsu Bio, Inc.	Whole cell and cell-debris polysaccharide
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
EP2123293A3 (fr) *	2000-12-14	2010-09-08	Amylin Pharmaceuticals, Inc.	Peptide YY et agonistes du peptide YY pour le traitement de troubles métaboliques
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
EP1474163A2 (fr)	2002-01-10	2004-11-10	Imperial College Innovations Limited	Modification des habitudes alimentaires
WO2003105763A2 (fr)	2002-06-14	2003-12-24	Amylin Pharmaceuticals, Inc.	Prevention et/ou traitement de maladie enterique inflammatoire au moyen de peptides yy ou d'antagonistes de peptides yy
AU2003290563A1 (en)	2002-10-31	2004-05-25	Clf Medical Technology Acceleration Program, Inc.	Leptin-related peptides
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
BRPI0411165A (pt) *	2003-05-14	2006-07-11	Emisphere Tech Inc	composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
JP6226510B2 (ja)	2012-01-27	2017-11-08	キヤノン株式会社	画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it)	2013-03-05	2014-09-06	Telecom Italia Spa	Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9602308B2 (en)	2014-06-23	2017-03-21	International Business Machines Corporation	Servicing packets in a virtual network and a software-defined network (SDN)
US9816387B2 (en)	2014-09-09	2017-11-14	United Technologies Corporation	Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (fr)	2015-03-31	2023-08-01	Allen-Vanguard Corporation	Recepteur de diffusion en continu du domaine temporel et du domaine de frequence
US9601471B2 (en)	2015-04-23	2017-03-21	Apple Inc.	Three layer stack structure
US9714199B2 (en)	2015-09-17	2017-07-25	I P Creations Limited	Concealed amalgamated explosive neutralizer and method of manufacture

2005
- 2005-02-11 NZ NZ579621A patent/NZ579621A/en not_active IP Right Cessation
- 2005-02-11 CA CA2555877A patent/CA2555877C/fr not_active Expired - Fee Related
- 2005-02-11 CA CA2849552A patent/CA2849552A1/fr not_active Abandoned
- 2005-02-11 NZ NZ548978A patent/NZ548978A/en not_active IP Right Cessation
- 2005-02-11 KR KR1020127004103A patent/KR20120034237A/ko not_active Ceased
- 2005-02-11 EP EP11176630A patent/EP2422806A3/fr not_active Withdrawn
- 2005-02-11 AU AU2005211755A patent/AU2005211755B2/en not_active Ceased
- 2005-02-11 CN CN201110061194.2A patent/CN102174115B/zh not_active Expired - Fee Related
- 2005-02-11 KR KR1020127032622A patent/KR101427024B1/ko not_active Expired - Fee Related
- 2005-02-11 EP EP20110176632 patent/EP2422807A3/fr not_active Withdrawn
- 2005-02-11 EP EP05722892.6A patent/EP1718665B1/fr not_active Expired - Lifetime
- 2005-02-11 RU RU2006132294/04A patent/RU2378285C2/ru not_active IP Right Cessation
- 2005-02-11 CN CN2005800120093A patent/CN1961000B/zh not_active Expired - Fee Related
- 2005-02-11 JP JP2006553217A patent/JP2007525495A/ja active Pending
- 2005-02-11 BR BRPI0507594-7A patent/BRPI0507594A/pt not_active IP Right Cessation
- 2005-02-11 EP EP11176627A patent/EP2417980A1/fr not_active Withdrawn
- 2005-02-11 WO PCT/US2005/004178 patent/WO2005077072A2/fr not_active Ceased
- 2005-02-11 CN CN201410138746.9A patent/CN103897066A/zh active Pending
- 2005-02-11 US US11/055,093 patent/US20060094652A1/en not_active Abandoned
- 2005-02-11 KR KR1020147001171A patent/KR20140011431A/ko not_active Ceased
- 2005-02-11 IN IN3921DEN2012 patent/IN2012DN03921A/en unknown
2006
- 2006-08-02 IL IL177229A patent/IL177229A0/en unknown
- 2006-08-29 ZA ZA200607190A patent/ZA200607190B/en unknown
2011
- 2011-06-21 JP JP2011137394A patent/JP5580784B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1718665A4 (fr)	2008-05-14
CN1961000B (zh)	2011-05-04
BRPI0507594A (pt)	2007-07-03
CA2849552A1 (fr)	2005-08-25
AU2005211755B2 (en)	2012-03-15
JP2011219488A (ja)	2011-11-04
EP1718665A2 (fr)	2006-11-08
EP2417980A1 (fr)	2012-02-15
NZ548978A (en)	2009-10-30
WO2005077072A2 (fr)	2005-08-25
CN103897066A (zh)	2014-07-02
ZA200607190B (en)	2007-11-28
JP5580784B2 (ja)	2014-08-27
AU2005211755A1 (en)	2005-08-25
RU2378285C2 (ru)	2010-01-10
EP2422807A3 (fr)	2012-05-30
CA2555877A1 (fr)	2005-08-25
EP2422806A3 (fr)	2012-06-13
NZ579621A (en)	2011-03-31
CN102174115A (zh)	2011-09-07
KR101427024B1 (ko)	2014-08-05
EP2422807A2 (fr)	2012-02-29
EP2422806A2 (fr)	2012-02-29
RU2006132294A (ru)	2008-03-20
IL177229A0 (en)	2006-12-10
WO2005077072A3 (fr)	2006-03-02
CN1961000A (zh)	2007-05-09
KR20140011431A (ko)	2014-01-28
JP2007525495A (ja)	2007-09-06
CA2555877C (fr)	2015-11-24
CN102174115B (zh)	2014-05-14
EP1718665B1 (fr)	2013-04-10
KR20120034237A (ko)	2012-04-10
US20060094652A1 (en)	2006-05-04
KR20130010086A (ko)	2013-01-25

Publication	Publication Date	Title
IN2012DN03921A (fr)	2015-09-04
Zheng et al.	2024	Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Martin et al.	2011	Incretin‐based therapies–review of the physiology, pharmacology and emerging clinical experience
Min et al.	2025	A Comprehensive Review on the Pharmacokinetics and Drug− Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
Lovshin et al.	2009	Incretin-based therapies for type 2 diabetes mellitus
Brandt et al.	2018	Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
JP6379300B2 (ja)	2018-08-22	ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
Madsbad	2016	Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Aroda et al.	2011	The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Holst et al.	2017	Semaglutide seems to be more effective the other GLP-1Ras
Peters	2010	Incretin-based therapies: review of current clinical trial data
JOP20250198A1 (ar)	2025-08-03	مركبات مساعدة مشتركة gip/glp1
ZA200606153B (en)	2007-12-27	Intranasal administration of glucose-regulating peptides
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
NO20074545L (no)	2007-11-09	GIP-analog og hybridpolypeptid med selekterbare egenskaper
WO2006024275A3 (fr)	2006-11-30	Invention concernant le glp-1 et l'exendine
Spezani et al.	2022	The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Ruscica et al.	2017	Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Grandl et al.	2024	Recent achievements and future directions of anti-obesity medications
Aylwin	2005	Gastrointestinal surgery and gut hormones
Bailey et al.	2025	Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Will et al.	2017	Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Alzahrani et al.	2025	Molecular pharmacology of glucagon-like peptide 1-based therapies in the management of type two diabetes mellitus and obesity
JP2019514908A5 (fr)	2020-06-11
Wu et al.	2023	Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes